Biotech Values

[DewDiligence]

MNTA: Regarding the [GS] presentation , what’s your take on the head of Sandoz commenting on possible a longer time line (brought up by someone asking questions)?

The purported distinction between the guidance on timing given by Jeff George of Sandoz and the guidance on timing given by Craig Wheeler does not exist, IMO. Neither NVS nor MNTA has any idea when the FDA will rule on the Lovenox ANDA, and hence comments from the companies on the timing of FDA action on the ANDA are useless from an investment standpoint.

Instead of focusing on the timing guidance that NVS/MNTA are unable to give, investors should focus on what the companies can say about the nature of the current discussions with the FDA. This is what I attempted to do in #msg-38561800. Regards, Dew